Mechanically tuned Lung-on-a-Chip device to model pathology and drug screening for lung disease

Projektinformationen

MECH-LoC

ID Finanzhilfevereinbarung: 793749

DOI 10.3030/793749

Abgeschlossenes Projekt

EK-Unterschriftsdatum 15 März 2018

Startdatum 15 Oktober 2018

Enddatum 14 Oktober 2020

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 173 076,00

EU-Beitrag € 173 076,00

Koordiniert durch

ELVESYS
France

Ziel

The aim of this project is to design a total lung-on-a-chip microfluidic device with a mechanically relevant air-liquid interface to create a cellular environment with more closely matched physiological and functional complexity than conventional lung models. Specifically, we will (i) integrate bronchiole and alveolar sac functional regions of the lung into one chip, and (ii) incorporate a relevant and tunable biomechanical profile into the gas-permeable membrane (mimic of air-liquid interface). This device will address the large and currently unmet need to model organ-level complexity of cells in vitro, in particular with regards to spatial and mechanical cues important for cell function, and provide a superior platform to model lung physiology, function and lung disease treatments. The project will be based on the state-of-the-art technical expertise of Elvesys in microfluidic chip design, fabrication and exquisite control of microfluidic parameters for advanced cell culture, and will fully integrate the Experienced Researcher’s (ER) strong expertise with elastic proteins, liquid interfaces, biomaterial design and mechanical testing to tune membrane stiffness and bioactivity by blending synthetic polymers and natural elastic proteins. Testing, validation and benchmarking of the product will be by perfusion using a set of candidate drugs chosen in consultation with clinician collaborators. This technology will offer clinicians a choice of lung model that is mechanically relevant to a patient’s lung profile (e.g. equivalent to physiological, stiffer or less stiff) for pre-screening of drug efficacy, dosing and toxicity.
Through this opportunity the ER will be immersed in a richly entrepreneurial environment at Elvesys and exposed to marketing concepts, IP and patenting. Together, these experiences will provide the ER with the optimal training environment to become a leader in regenerative medicine.

Wissenschaftliches Gebiet

• natural sciences › physical sciences › classical mechanics › fluid mechanics › microfluidics
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › basic medicine › pathology
• medical and health sciences › basic medicine › physiology

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2017 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2017

Finanzierungsplan

MSCA-IF-EF-SE - Society and Enterprise panel

Koordinator

ELVESYS

• Netto-EU-Beitrag: € 173 076,00
• Adresse: 172 RUE DE CHARONNE B2 2 EME ETAGE ; 75011 Paris ; Frankreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ile-de-France › Ile-de-France › Paris
• Region: Ile-de-France › Ile-de-France › Paris
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 173 076,00